Hantz Financial Services Inc. Reduces Stake in AbbVie Inc. (NYSE:ABBV)

Hantz Financial Services Inc. lowered its holdings in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 3.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 46,028 shares of the company's stock after selling 1,817 shares during the period. Hantz Financial Services Inc.'s holdings in AbbVie were worth $8,179,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Forsta AP Fonden increased its holdings in shares of AbbVie by 1.3% during the fourth quarter. Forsta AP Fonden now owns 458,562 shares of the company's stock valued at $81,486,000 after acquiring an additional 5,800 shares in the last quarter. Patton Fund Management Inc. acquired a new position in AbbVie during the fourth quarter worth $5,058,000. Foster Victor Wealth Advisors LLC lifted its stake in shares of AbbVie by 19.4% in the fourth quarter. Foster Victor Wealth Advisors LLC now owns 75,059 shares of the company's stock valued at $12,877,000 after buying an additional 12,214 shares in the last quarter. Robeco Institutional Asset Management B.V. raised its holdings in shares of AbbVie by 3.2% in the 4th quarter. Robeco Institutional Asset Management B.V. now owns 3,678,683 shares of the company's stock worth $653,702,000 after acquiring an additional 112,925 shares during the last quarter. Finally, Twelve Points Wealth Management LLC lifted its position in AbbVie by 10.5% in the 4th quarter. Twelve Points Wealth Management LLC now owns 6,777 shares of the company's stock valued at $1,204,000 after acquiring an additional 642 shares in the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several brokerages have recently commented on ABBV. Barclays increased their price objective on AbbVie from $200.00 to $212.00 and gave the stock an "overweight" rating in a research note on Monday, October 7th. Leerink Partnrs upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Friday, November 22nd. Wells Fargo & Company lifted their price objective on shares of AbbVie to $195.00 and gave the stock a "buy" rating in a report on Tuesday, November 19th. JPMorgan Chase & Co. lowered their target price on shares of AbbVie from $210.00 to $200.00 and set an "overweight" rating for the company in a report on Wednesday, November 13th. Finally, Daiwa Capital Markets cut shares of AbbVie from an "outperform" rating to a "neutral" rating and set a $180.00 price target on the stock. in a report on Thursday, December 5th. Five investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $205.00.

AbbVie Trading Up 0.2 %

Shares of NYSE:ABBV traded up $0.35 on Thursday, hitting $175.61. The company had a trading volume of 1,486,895 shares, compared to its average volume of 5,712,993. AbbVie Inc. has a 1 year low of $153.58 and a 1 year high of $207.32. The company has a quick ratio of 0.54, a current ratio of 0.65 and a debt-to-equity ratio of 9.64. The firm's 50-day simple moving average is $176.37 and its two-hundred day simple moving average is $184.90. The firm has a market capitalization of $310.33 billion, a price-to-earnings ratio of 60.97, a P/E/G ratio of 1.68 and a beta of 0.58.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.92 by $0.08. The business had revenue of $14.46 billion for the quarter, compared to analysts' expectations of $14.28 billion. AbbVie had a return on equity of 244.01% and a net margin of 9.22%. The business's revenue was up 3.8% on a year-over-year basis. During the same period in the previous year, the firm posted $2.95 EPS. Equities analysts anticipate that AbbVie Inc. will post 10.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the company's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $172.24, for a total value of $310,032.00. Following the sale, the senior vice president now owns 6,983 shares in the company, valued at $1,202,751.92. This represents a 20.49 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 0.25% of the stock is owned by corporate insiders.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.